BlueRock opens site on Bayer's Berlin campus

8 June 2022

Bayer’s (BAYN: DE) wholly-owned subsidiary BlueRock Therapeutics has established a new site for cell therapy innovation on the German pharma major’s campus in Berlin.

While operating independently, the team at Boston-headquartered BlueRock will benefit from the expertise of various teams at Bayer to enable the expansion and acceleration of the company’s clinical trials to Europe.

"A significant step forward in advancing our leadership in cell therapies globally"BlueRock recently closed enrollment for a Phase I clinical trial for BRT-DA01, its novel cell therapy for treating Parkinson’s disease, and intends to begin a global non-interventional study for Parkinson’s patients in the second half of 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK